An upcoming Phase 2 clinical trial is set to evaluate Novocure‘s Tumor Treating Fields, known as TTFields, in combination with Keytruda (pembrolizumab) for the treatment of non-small cell lung cancer (NSCLC). TTFields is a treatment method that uses electric fields tuned to specific frequencies to interrupt cancer cell division, causing cancer cells to die and limiting tumor growth. The therapy has minimal effects on non-cancerous cells. In the U.S., TTFields is approved to treat mesothelioma and…
You must be logged in to read/download the full post.
The post Novocure, MSD Team Up to Test TTFields-Keytruda Combo in Lung Cancer appeared first on BioNewsFeeds.